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Abstract
© 2016 Lada Dyachenko et al.Purpose. To investigate a frequency of antibody response to
SEREX-identified medullary breast carcinoma autoantigens ZRF1 and KRR1 in sera of breast
cancer patients taking into account clinical and molecular characteristics of tumors for opening
of  new  perspectives  in  creation  of  minimally  invasive  immunological  tests  for  cancer
diagnostics. Methods. Enzyme-linked immunosorbent assay and bioinformatics analysis. Results.
Increased frequency of antibody response was found in sera of breast cancer patients to ZRF
and KRR1 antigens. The antibody response to these antigens was higher in sera of patients with
invasive ductal carcinoma than in sera of patients with other histological types of breast tumors.
Moreover, more frequent antibody response to ZRF antigen was found in sera of patients with
less aggressive tumors. The sequence analysis of ZRF1 antigen SEREX clones obtained from
cDNA libraries of different tumors demonstrates that they encode different protein isoforms.
Conclusion. Tumor-associated antigens KRR1 and ZRF1 and their cognate autoantibodies could
be considered  as  potential  molecular  markers  of  breast  cancer  which  need to  be  further
investigated.
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